Antithrombotic and antilesion benefits without hemorrhagic risks by inhibiting tissue factor pathway

Pathophysiology of Haemostasis and Thrombosis

Volumn 26, Issue , 1996, Pages 76-82

  Harker, Laurence A ^a   Hanson, Stephen R ^a   Wilcox, Josiah N ^a   Kelly, Andrew B ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Angioplasty; Endarterectomy; Tissue factor; Vascular neointimal lesion formation; Vascular thrombosis

Indexed keywords

BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 7A; THROMBOPLASTIN;

ANGIOPLASTY; ANIMAL EXPERIMENT; ANIMAL MODEL; BABOON; BLOOD CLOTTING; CONFERENCE PAPER; DRUG THERAPY; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; PREVENTION; PRIORITY JOURNAL; THROMBOGENESIS;

AMINO ACID SEQUENCE; ASPIRIN; DRUG RESISTANCE; FACTOR VIIA; FIBRINOLYTIC AGENTS; HUMANS; MOLECULAR SEQUENCE DATA; RECOMBINANT PROTEINS; RISK FACTORS; THROMBOPLASTIN;

EID: 0029984412     PISSN: 14248832     EISSN: 14248840     Source Type: Journal    
DOI: 10.1159/000217245     Document Type: Article

References (25)

1. Antiplatelet Trialists' Collaboration: Secondary prevention of vascular disease by prolonged antiplatc-let treatment. Br Med J 1988;296: 320-331.
2. Antiplatelet Trialists’ Collaboration: Collaborative overview of randomized trials of antiplatelct therapy. I. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Br Med J 1994:308:81-106.
3. Chesebro JH, Fuster V: The therapeutic challenge of plaque rupture: Value of biochemical markers. J Am Coll Cardiol 1987:10:1005.
4. Hanson SR, Harkcr LA: Interruption of acute platelet-dependent thrombosis by the synthetic antithrombin ZJ-phenylalanyl-L-prolyl-/.-arginyl chloromethylkctonc. Proc Natl Acad Sci USA 1988:85:3184-3188.
5. Phillips DR, Charo IF, Scarborough RM: GPIIb-IIIa: The responsive in-tegrin. Cell 1991;65:359-362.
6. Colter BS: Platelets and thrombolytic therapy. N Engl J Med 1990:322: 33-42.
7. Harker LA, Maraganore JM. Hirsh J: Novel antithrombotic agents; in Colman RW, Hirsh J, Mardcr VJ, Salzman EW (eds): Hemostasis and Thrombosis: Basic Principles and Clinical Practice, cd 3. Philadelphia, Lippincott, 1994, pp 1638-1660.
8. Furie B, Furic BC: Molecular and cellular biology of blood coagulation. N Engl J Med 1992;326:800-806.
9. Morrissey JH, Fakhrai H, Edgington TS: Molecular cloning of the cDNA for tissue factor, the cellular receptor for the initiation of the coagulation protease cascade. Cell 1987,50:129-135.
10. Krishnaswamy S, Field KA, Eding-ton TS. Morrissey JH, Mann KG: Role of the membrane surface in the activation of human coagulation factor X. J Biol Chcm 1992:267: 26110-26120.
11. Weitz JL. Hudoba M, Massel D. Ma raganore J, Hirsh J: Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin Ill-independent inhibitors. J Clin Invest 1990:86:385-391.
12. Dodt J. Seemuller U. Maschler R. Fritz H: The complete covalent structure of hirudin. Localisation of the disulfide bonds. Biol Chem Hoppe Scylcr 1985;366:379-385.
13. Kelly AB. Maraganore JM, Bourdon P, Hanson SR. Harker LA: Antithrombotic effects of synthetic peptides targeting different functional domains of thrombin. Proc Natl Acad Sci USA 1992;89:6040-6044.
14. Kelly AB, Marzec UM, Krupski W. Bass A. Cadroy Y. Hanson SR. et al: Hirudin interruption of heparin-resistant arterial thrombus formation in baboons. Blood 1991;77:1006-1012.
15. Amman EM. TIMI 9A Investigators: Hirudin in acute myocardial infarction: Safety report from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9A Trial. Circulation 1994; 90:1624-1630.
16. GUSTO Ila Investigators: Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary' syndromes. Circulation 1994:60:1631-1637.
17. Hanson SR, Pareti FI, Ruggeri ZM, Kunicki TJ. Montgomery RR. Zimmerman TS. et al: Effects of monoclonal antibodies against the platelet glycoprotein Ilb/Illa complex on thrombosis and hemostasis in the baboon. J Clin Invest 1988:81:149-158.
18. The EPIC Investigators: Use of a monoclonal antibody directed against the platelet glycoprotein lib/ Ilia recpetor in high-risk coronary angioplasty. N Engl J Med 1994; 330:956-961.
19. Harker LA: Platelets and vascular thrombosis. N Engl J Med 1994; 330:1006-1007.
20. Charo IF, Nannizzi L, Phillips DR, Hsu MA, Scarborough RM: Inhibition of fibrinogen binding toGP 11b-Illa by a GP Ilia peptide. J Biol Chem 1991;266:1415-1421.
21. Saltiel E, Ward A: Ticlopidinc. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in platclet-dc-pendent disease states. Drugs 1987; 34:222.
22. Hass WK, Easton JD, Adams HP: A randomized trial comparing ticlopidinc hydrochloride with aspirin for the prevention of stroke in high-risk patients. N Engl J Med 1989: 321:501.
23. Gent M, Blakely JA, Easton JD: The Canadian American Ticlopidinc Study (CATS) in thromboembolic stroke. Lancet 1989;vol i: 1215.
24. Janzon L, Bergqvist D, Boberg J. et al: Prevention of myocardial infarction and stroke in patients with intermittent claudication: Effects of ti-clopidine. Results from STIMS, the Swedish Ticlopidinc Multicentre Study. Scand J Intern Med 1990: 227:301.
25. Balsano F, Rizzon P, Violi F, et al: Antiplatclct treatment with ticlopidinc in unstable angina. A controlled multicenter clinical trial. Circulation 1990:82:17.